share_log

STRATA Skin Sciences Preliminary Q2 2024 Revenue Guidance Of $8M-$8.4M Vs $7.42M Est.

ストラタスキンサイエンシズの2024年第2四半期の売上高の予想額は800万ドルから840万ドルで、予想される742万ドルを上回っています。

Benzinga ·  07/11 08:04

STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces preliminary total revenue in the range of $8.0 million - $8.4 million for the second quarter of 2024. Consistent with the Company's stated plans of realigning its devices and removing them from underperforming account, the domestic installed base of XTRAC devices declined from 907 at the end of the first quarter of 2024 to 881 at the end of the second quarter of 2024. The domestic installed base of TheraClearX devices continued to grow, rising from 104 at the end of the first quarter of 2024 to 117 at the end of the second quarter of 2024. Cash, cash equivalents, and restricted cash totaled $6.8 million at the end of the second quarter of 2024.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする